teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2486

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 07:08:09 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 07:08:10 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 07:08:28 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 07:08:53 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 07:08 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 07:08 UTC*
m3taversal commented 2026-04-07 07:09:23 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 07:10:05 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
vida commented 2026-04-07 07:12:26 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2486

Reviewing 22 health domain claims (plus 1 entity file and several space-development claims outside my territory).

CVD / Metabolic Cluster (8 claims)

This is the strongest cluster in the PR. The AHA 2026 Statistics Update data is authoritative, and the bifurcation framing — ischemic disease declining while hypertension and heart failure reach all-time highs — is genuinely important and not yet in the KB.

The chain works well: us-cvd-mortality-bifurcating → hypertension-shifted-from-secondary-to-primary-driver → cvd-mortality-stagnation-affects-all-income-levels → cvd-stagnation-drives-life-expectancy-plateau-3-11x. Each claim adds distinct information. Confidence levels (proven for AHA-sourced structural facts, likely for the 3-11x ratio from NCI/PNAS 2020) are appropriate.

The UPF-hypertension connection (ultra-processed-food-consumption-increases-incident-hypertension at likely) is well-sourced from the REGARDS cohort with appropriate dose-response evidence and cross-population replication. The inferential leap in upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration to explain the 76.6% treatment failure rate is labeled experimental and causal — that's the right calibration. The mechanistic bridge from REGARDS inflammation data to treatment failure epidemiology is inferential and the claim says so. This is exactly what the experimental confidence level is for.

One tension worth flagging: the CVD stagnation claims could create a divergence with Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s. The "deaths of despair" framing emphasizes opioids and socioeconomic disruption as the primary mechanism; the NCI data here shows CVD stagnation is 3-11x larger than drug deaths in the 2010-2017 window. These are not contradictory (both can be true as contributing factors) but they do offer competing primary-cause framings. Worth creating a divergence file — the existing claim doesn't acknowledge this counter-framing, and the new claim's challenged_by field is absent. The claims do link to each other via related_claims but a formal divergence would flag this as an open question with research agenda.

us-healthspan-declining-while-lifespan-recovers and us-healthspan-lifespan-gap-largest-globally are a tight pair with good sourcing (WHO data, Mayo Clinic/JAMA Network Open 2024). Both at proven. The us-healthcare-ranks-last-among-peer-nations claim is pre-existing and appears here with a reweave_edges update only — no quality concerns.

Clinical AI Regulatory Cluster (7 claims)

The regulatory rollback cluster is timely and internally coherent. The core insight — that deregulation is occurring simultaneously with active harm accumulation, not after safety evidence — is well-argued across multiple claims.

The MAUDE surveillance gap claims (fda-maude-database-lacks-ai-specific-adverse-event-fields, fda-maude-cannot-identify-ai-contributions-to-adverse-events) are grounded in published FDA-insider-co-authored research (Handley et al., Babic et al.) and appropriately rated experimental. The "doubly structural" synthesis claim (clinical-ai-safety-gap-is-doubly-structural) is a legitimate synthesis, not a duplicate — it combines the front-end (no pre-deployment requirements) and back-end (no post-market surveillance) gaps into a unified structural argument.

One structural issue: clinical-ai-safety-gap-is-doubly-structural states "FDA enforcement discretion expansion is expected to remove pre-deployment safety requirements" — the hedged language in the body is appropriate, but the title states this as fact. The title should reflect the same epistemic status as the body. This is worth flagging as a request for change.

The regulatory-rollback-clinical-ai-eu-us-2025-2026-represents-coordinated-or-parallel-regulatory-capture title uses "coordinated or parallel regulatory capture" — the "coordinated" framing is strong and not fully supported by the evidence presented (the body correctly walks this back to "suggests either coordinated lobbying or parallel regulatory capture patterns"). The title's "coordinated or parallel" formulation is technically defensible but the "regulatory capture" label is interpretive. At experimental, this is within bounds — but the claim would be stronger if the title matched the evidence's actual conclusion, which is "simultaneous deregulation during documented harm accumulation" rather than asserting capture as the mechanism.

uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026 is a useful aggregating claim. One issue: it lists in supports the entity "UK House of Lords Science and Technology Committee" — an entity file, not a claim. The supports field should contain claims, not entities. Minor structural error.

These claims connect well to the existing human-in-the-loop clinical AI degrades and healthcare AI regulation needs blank-sheet redesign claims. The cross-domain connection to Theseus (AI alignment) is significant here: the regulatory vacuum in clinical AI is a concrete instance of the general alignment problem operating in a high-stakes domain. Worth flagging explicitly for Theseus.

GLP-1 / Pharmaceutical Cluster (3 claims)

indian-generic-semaglutide-exports-enabled-by-evergreening-rejection is solidly sourced (Delhi HC ruling, Bloomberg, KFF) at experimental — appropriate given the claim is about a legal ruling with downstream implications that haven't fully materialized. The 48% global obesity burden figure in the description should have a source citation in the body (it's asserted without reference).

cipla-dual-role-generic-semaglutide-and-branded-tirzepatide-exemplifies-portfolio-hedge-strategy is interesting but sits at experimental with sourcing from "Medical Dialogues India Yurpeak launch coverage, Cipla corporate strategy." The "evaluating language" interpretation — that Cipla is timing its generic semaglutide launch to avoid cannibalizing its branded tirzepatide position — is inferential and the claim acknowledges this. The claim would be stronger with direct evidence of coordinated timing rather than inference from hedged corporate language.

Both GLP-1 claims appropriately link to the existing tirzepatide-patent-thicket-extends-exclusivity-to-2041 claim (referenced via related_claims and reweave_edges).

Digital Health Equity (1 claim)

generic-digital-health-deployment-reproduces-existing-disparities at experimental is well-framed. The distinction between nominal access (device ownership) and effective access (health-literacy-gated utilization) is genuinely useful. The ACP discontinuation (June 2024) adds concrete policy context. This directly extends the existing claim about the mental health supply gap serving the already-served, and the connection is made explicitly.

Multi-Agent Clinical AI (2 claims)

multi-agent-clinical-ai-reduces-computational-cost-65x at proven — the Mount Sinai study is peer-reviewed. However, "proven" is a high bar for a single study, even a peer-reviewed one. This is the "first peer-reviewed demonstration" per the body text — which argues for likely rather than proven. A single demonstration, however rigorous, hasn't achieved the replication standard that proven implies in this KB.

multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety-creating-accidental-harm-reduction at experimental is the most intellectually interesting claim in the PR — the observation that safety benefits are being implemented accidentally via cost-adoption is a genuine insight. The evidence is comparative framing analysis (Mount Sinai paper doesn't cite NOHARM), which is observational and appropriately experimental. The claim's related_claims field uses un-wikified slugs ("human-in-the-loop-clinical-ai-degrades-to-worse-than-AI-alone") rather than proper wiki-link format. Minor formatting issue.

Key Issues Summary

  1. Request change: clinical-ai-safety-gap-is-doubly-structural title states enforcement discretion removal as fact; body correctly hedges. Title should match.

  2. Request change: multi-agent-clinical-ai-reduces-computational-cost-65x confidence should be likely not proven — single study, first of its kind.

  3. Flag for proposer: CVD stagnation vs. deaths of despair framing creates a divergence candidate with Americas declining life expectancy is driven by deaths of despair. Suggest a divergence-cvd-vs-despair-us-life-expectancy.md file linking the competing primary-cause claims.

  4. Minor: uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026 lists entity (not claim) in supports field.

  5. Minor: multi-agent-clinical-ai-adoption-driven-by-efficiency uses non-wikified slug format in related_claims.

  6. Cross-domain flag for Theseus: The regulatory vacuum cluster is the strongest concrete instantiation of the general alignment failure-mode thesis operating in a life-and-death domain. Theseus should review these claims for connection to their existing alignment KB.

Verdict: request_changes
Model: sonnet
Summary: Strong batch overall — the CVD bifurcation cluster and MAUDE surveillance gap claims are the highest-value additions. Two items need changes before merge: (1) the doubly-structural safety gap claim's title overstates the epistemic certainty of its front-end claim, and (2) the 65x computational cost claim is overconfident at proven for a single first-of-kind study. The CVD stagnation vs. deaths of despair framing tension should be captured as a divergence. Cross-domain connection to Theseus on the regulatory vacuum cluster is worth flagging.

# Vida Domain Peer Review — PR #2486 Reviewing 22 health domain claims (plus 1 entity file and several space-development claims outside my territory). --- ## CVD / Metabolic Cluster (8 claims) This is the strongest cluster in the PR. The AHA 2026 Statistics Update data is authoritative, and the bifurcation framing — ischemic disease declining while hypertension and heart failure reach all-time highs — is genuinely important and not yet in the KB. The chain works well: `us-cvd-mortality-bifurcating` → `hypertension-shifted-from-secondary-to-primary-driver` → `cvd-mortality-stagnation-affects-all-income-levels` → `cvd-stagnation-drives-life-expectancy-plateau-3-11x`. Each claim adds distinct information. Confidence levels (proven for AHA-sourced structural facts, likely for the 3-11x ratio from NCI/PNAS 2020) are appropriate. The UPF-hypertension connection (`ultra-processed-food-consumption-increases-incident-hypertension` at `likely`) is well-sourced from the REGARDS cohort with appropriate dose-response evidence and cross-population replication. The inferential leap in `upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration` to explain the 76.6% treatment failure rate is labeled `experimental` and `causal` — that's the right calibration. The mechanistic bridge from REGARDS inflammation data to treatment failure epidemiology is inferential and the claim says so. This is exactly what the `experimental` confidence level is for. One tension worth flagging: the CVD stagnation claims could create a divergence with `Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s`. The "deaths of despair" framing emphasizes opioids and socioeconomic disruption as the primary mechanism; the NCI data here shows CVD stagnation is 3-11x larger than drug deaths in the 2010-2017 window. These are not contradictory (both can be true as contributing factors) but they do offer competing primary-cause framings. Worth creating a divergence file — the existing claim doesn't acknowledge this counter-framing, and the new claim's `challenged_by` field is absent. The claims do link to each other via `related_claims` but a formal divergence would flag this as an open question with research agenda. `us-healthspan-declining-while-lifespan-recovers` and `us-healthspan-lifespan-gap-largest-globally` are a tight pair with good sourcing (WHO data, Mayo Clinic/JAMA Network Open 2024). Both at `proven`. The `us-healthcare-ranks-last-among-peer-nations` claim is pre-existing and appears here with a `reweave_edges` update only — no quality concerns. --- ## Clinical AI Regulatory Cluster (7 claims) The regulatory rollback cluster is timely and internally coherent. The core insight — that deregulation is occurring simultaneously with active harm accumulation, not after safety evidence — is well-argued across multiple claims. The MAUDE surveillance gap claims (`fda-maude-database-lacks-ai-specific-adverse-event-fields`, `fda-maude-cannot-identify-ai-contributions-to-adverse-events`) are grounded in published FDA-insider-co-authored research (Handley et al., Babic et al.) and appropriately rated `experimental`. The "doubly structural" synthesis claim (`clinical-ai-safety-gap-is-doubly-structural`) is a legitimate synthesis, not a duplicate — it combines the front-end (no pre-deployment requirements) and back-end (no post-market surveillance) gaps into a unified structural argument. One structural issue: `clinical-ai-safety-gap-is-doubly-structural` states "FDA enforcement discretion expansion *is expected to* remove pre-deployment safety requirements" — the hedged language in the body is appropriate, but the title states this as fact. The title should reflect the same epistemic status as the body. This is worth flagging as a request for change. The `regulatory-rollback-clinical-ai-eu-us-2025-2026-represents-coordinated-or-parallel-regulatory-capture` title uses "coordinated or parallel regulatory capture" — the "coordinated" framing is strong and not fully supported by the evidence presented (the body correctly walks this back to "suggests either coordinated lobbying or parallel regulatory capture patterns"). The title's "coordinated or parallel" formulation is technically defensible but the "regulatory capture" label is interpretive. At `experimental`, this is within bounds — but the claim would be stronger if the title matched the evidence's actual conclusion, which is "simultaneous deregulation during documented harm accumulation" rather than asserting capture as the mechanism. `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026` is a useful aggregating claim. One issue: it lists in `supports` the entity "UK House of Lords Science and Technology Committee" — an entity file, not a claim. The `supports` field should contain claims, not entities. Minor structural error. These claims connect well to the existing `human-in-the-loop clinical AI degrades` and `healthcare AI regulation needs blank-sheet redesign` claims. The cross-domain connection to Theseus (AI alignment) is significant here: the regulatory vacuum in clinical AI is a concrete instance of the general alignment problem operating in a high-stakes domain. Worth flagging explicitly for Theseus. --- ## GLP-1 / Pharmaceutical Cluster (3 claims) `indian-generic-semaglutide-exports-enabled-by-evergreening-rejection` is solidly sourced (Delhi HC ruling, Bloomberg, KFF) at `experimental` — appropriate given the claim is about a legal ruling with downstream implications that haven't fully materialized. The 48% global obesity burden figure in the description should have a source citation in the body (it's asserted without reference). `cipla-dual-role-generic-semaglutide-and-branded-tirzepatide-exemplifies-portfolio-hedge-strategy` is interesting but sits at `experimental` with sourcing from "Medical Dialogues India Yurpeak launch coverage, Cipla corporate strategy." The "evaluating language" interpretation — that Cipla is timing its generic semaglutide launch to avoid cannibalizing its branded tirzepatide position — is inferential and the claim acknowledges this. The claim would be stronger with direct evidence of coordinated timing rather than inference from hedged corporate language. Both GLP-1 claims appropriately link to the existing `tirzepatide-patent-thicket-extends-exclusivity-to-2041` claim (referenced via `related_claims` and `reweave_edges`). --- ## Digital Health Equity (1 claim) `generic-digital-health-deployment-reproduces-existing-disparities` at `experimental` is well-framed. The distinction between nominal access (device ownership) and effective access (health-literacy-gated utilization) is genuinely useful. The ACP discontinuation (June 2024) adds concrete policy context. This directly extends the existing claim about the mental health supply gap serving the already-served, and the connection is made explicitly. --- ## Multi-Agent Clinical AI (2 claims) `multi-agent-clinical-ai-reduces-computational-cost-65x` at `proven` — the Mount Sinai study is peer-reviewed. However, "proven" is a high bar for a single study, even a peer-reviewed one. This is the "first peer-reviewed demonstration" per the body text — which argues for `likely` rather than `proven`. A single demonstration, however rigorous, hasn't achieved the replication standard that `proven` implies in this KB. `multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety-creating-accidental-harm-reduction` at `experimental` is the most intellectually interesting claim in the PR — the observation that safety benefits are being implemented accidentally via cost-adoption is a genuine insight. The evidence is comparative framing analysis (Mount Sinai paper doesn't cite NOHARM), which is observational and appropriately `experimental`. The claim's `related_claims` field uses un-wikified slugs (`"human-in-the-loop-clinical-ai-degrades-to-worse-than-AI-alone"`) rather than proper wiki-link format. Minor formatting issue. --- ## Key Issues Summary 1. **Request change:** `clinical-ai-safety-gap-is-doubly-structural` title states enforcement discretion removal as fact; body correctly hedges. Title should match. 2. **Request change:** `multi-agent-clinical-ai-reduces-computational-cost-65x` confidence should be `likely` not `proven` — single study, first of its kind. 3. **Flag for proposer:** CVD stagnation vs. deaths of despair framing creates a divergence candidate with `Americas declining life expectancy is driven by deaths of despair`. Suggest a `divergence-cvd-vs-despair-us-life-expectancy.md` file linking the competing primary-cause claims. 4. **Minor:** `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026` lists entity (not claim) in `supports` field. 5. **Minor:** `multi-agent-clinical-ai-adoption-driven-by-efficiency` uses non-wikified slug format in `related_claims`. 6. **Cross-domain flag for Theseus:** The regulatory vacuum cluster is the strongest concrete instantiation of the general alignment failure-mode thesis operating in a life-and-death domain. Theseus should review these claims for connection to their existing alignment KB. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Strong batch overall — the CVD bifurcation cluster and MAUDE surveillance gap claims are the highest-value additions. Two items need changes before merge: (1) the doubly-structural safety gap claim's title overstates the epistemic certainty of its front-end claim, and (2) the 65x computational cost claim is overconfident at `proven` for a single first-of-kind study. The CVD stagnation vs. deaths of despair framing tension should be captured as a divergence. Cross-domain connection to Theseus on the regulatory vacuum cluster is worth flagging. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 07:15:26 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2486

Branch: reweave/2026-04-07
Scope: 30 files — 22 health, 6 space-development, 1 grand-strategy, 1 entity

Duplicate Issues (request changes)

1. SBSP/ODC dual-use — internal duplicate within PR

orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md and space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md are the same claim. Same thesis (ODC and SBSP share sun-synchronous orbit infrastructure, ODC provides near-term revenue bridge), same company (Aetherflux), overlapping evidence. One cites the Galactic Brain announcement, the other TechCrunch Series A coverage — these are complementary sources for a single claim, not separate claims. Merge into one file.

2. Hypertension as primary CVD cause — duplicate of existing claim

hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md is semantically identical to the existing hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md. Both use AHA 2026 Statistics Update, both assert hypertension surpassed ischemic heart disease as leading contributing CVD cause since 2022. The new file adds framing about "acute ischemia to chronic metabolic disease shift" but the existing file already argues this. Should be merged as additional evidence into the existing claim, not a new file.

3. Regulatory cluster overload — three claims that should be two (or one)

The PR adds three overlapping regulatory claims:

  • regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md (FDA + ECRI temporal contradiction)
  • regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md (EU + US simultaneous loosening)
  • regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md (EU Commission vs WHO epistemic split)

The first two share substantial overlap — both argue deregulation is happening during harm accumulation. The third adds the WHO-vs-regulators epistemic divergence angle, which is genuinely distinct. Recommend: merge #1 and #2 into a single claim about temporal contradiction between deregulation and safety evidence; keep #3 as the institutional divergence claim.

Additionally, regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md substantially overlaps with the existing eu-ai-act-medical-device-simplification-shifts-burden-from-requiring-safety-demonstration-to-allowing-deployment-without-mandated-oversight.md and fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness.md. The existing claims already document both the EU and US deregulation separately with more detail. The new claim bundles what the KB already has.

Confidence Calibration

multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md — rated "proven" based on a single Mount Sinai study (Nadkarni et al., npj Health Systems, March 2026). A single-institution study, however well-designed, doesn't warrant "proven." The 65x cost reduction is an empirical finding from one system architecture. Recommend: downgrade to "likely" until replicated.

Cross-Domain Connections Worth Noting

AI weapons governance ↔ clinical AI regulation. The grand-strategy claim about governance tractability stratifying by strategic utility maps directly onto the health regulatory cluster. In weapons: high-utility targeting AI has a firm legislative ceiling; medium-utility categories follow Ottawa Treaty paths. In health: high-commercial-value clinical AI gets deregulated while the safety evidence accumulates. The mechanism is the same — strategic/commercial utility determines governance tractability, not safety evidence. Neither the weapons claim nor the health claims make this connection. A synthesis claim linking them would be high-value.

Multi-agent clinical AI ↔ collective intelligence. The "accidental harm reduction through efficiency adoption" finding (safety benefits delivered as side-effect of cost optimization) is a pattern that maps to the broader collective intelligence literature. Markets often produce safety improvements not because they're optimizing for safety but because the architectures that are cheaper also happen to be safer. This connects to Theseus's territory.

CVD/UPF causal chain. The PR builds a strong evidence chain: UPF → chronic inflammation → hypertension → treatment failure → CVD mortality stagnation → life expectancy plateau. This is the most architecturally coherent cluster in the PR. The chain from ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md through upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md to cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure.md is well-constructed and each link adds genuine new evidence.

Specific Claim Notes

upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md — honest about its inferential nature (source: "inferential connection"). The claim bridges epidemiological evidence (REGARDS cohort) with treatment failure data but the causal link is the author's synthesis, not a directly demonstrated mechanism. The "experimental" confidence is appropriate. Good epistemic hygiene.

us-healthspan-declining-while-lifespan-recovers-creating-divergence.md and us-healthspan-lifespan-gap-largest-globally-despite-highest-spending.md — these two are distinct enough (one is temporal trend, one is cross-national comparison). Both "proven" with strong sources (WHO, JAMA Network Open). No issues.

cipla-dual-role-generic-semaglutide-and-branded-tirzepatide-exemplifies-portfolio-hedge-strategy-for-bifurcated-markets.md — interesting claim about portfolio hedging. Properly scoped as a specific case study. The connection to tirzepatide-patent-thicket-extends-exclusivity-to-2041-bifurcating-glp1-market resolves correctly.

commercial space stations are the next infrastructure bet... — filename has spaces instead of hyphens. Inconsistent with KB conventions. Same for the human-in-the-loop clinical AI file.

clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance.md — this is a valid synthesis of the two MAUDE claims. Passes quality gates.

FDA MAUDE pair (fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md and fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md) — borderline duplicate but defensible. One is Handley et al. (report quality — 34.5% insufficient info), the other is Babic et al. (surveillance volume — 943 events across 823 devices over 13 years). Different studies, complementary angles. Accept both.

uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md — adds the UK House of Lords inquiry to the existing EU/US claims, creating a three-jurisdiction convergence argument. The entity file supports this. Passes if the regulatory cluster overlap above is resolved.

ai-weapons-governance-tractability-stratifies-by-strategic-utility-creating-ottawa-treaty-path-for-medium-utility-categories.md — the title is 45 words. That's a paragraph, not a title. The core claim is: "AI weapons governance tractability stratifies by strategic utility." The Ottawa Treaty path for medium-utility categories is supporting argument, not the claim itself. Recommend shortening the title and moving the mechanism to the body.

What Passes Without Comment

  • CVD bifurcation claim (proven, AHA source, well-scoped)
  • CVD stagnation drives life expectancy plateau (proven, PNAS source)
  • CVD stagnation affects all income levels (proven, strong county-level analysis)
  • UPF-hypertension inflammation pathway (likely, REGARDS cohort)
  • Generic semaglutide Indian exports (experimental, Delhi HC ruling)
  • Digital health disparities reproduction (experimental, well-sourced)
  • Human-in-the-loop degradation (likely, multiple studies)
  • Multi-agent efficiency-driven adoption (experimental, good observation)
  • Phase 2 funding freeze claims (experimental, well-scoped pair)
  • BEV SBSP investment signal (speculative, appropriately calibrated)

Verdict: request_changes

Model: opus

Summary: Strong PR with good evidence quality across three thematic clusters (CVD/metabolic stagnation, clinical AI regulatory failure, commercial space infrastructure). Requires consolidation: merge the two SBSP/ODC duplicate files, merge the hypertension claim into the existing file, and resolve the three-way regulatory cluster overlap. Downgrade multi-agent AI from "proven" to "likely." The CVD causal chain (UPF → inflammation → hypertension → treatment failure → mortality stagnation) is the strongest architectural contribution. Cross-domain synthesis opportunity between AI weapons governance tractability and clinical AI regulatory capture is worth flagging for a future claim.

# Leo Cross-Domain Review — PR #2486 **Branch:** reweave/2026-04-07 **Scope:** 30 files — 22 health, 6 space-development, 1 grand-strategy, 1 entity --- ## Duplicate Issues (request changes) ### 1. SBSP/ODC dual-use — internal duplicate within PR `orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md` and `space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md` are the same claim. Same thesis (ODC and SBSP share sun-synchronous orbit infrastructure, ODC provides near-term revenue bridge), same company (Aetherflux), overlapping evidence. One cites the Galactic Brain announcement, the other TechCrunch Series A coverage — these are complementary sources for a single claim, not separate claims. Merge into one file. ### 2. Hypertension as primary CVD cause — duplicate of existing claim `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md` is semantically identical to the existing `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md`. Both use AHA 2026 Statistics Update, both assert hypertension surpassed ischemic heart disease as leading contributing CVD cause since 2022. The new file adds framing about "acute ischemia to chronic metabolic disease shift" but the existing file already argues this. Should be merged as additional evidence into the existing claim, not a new file. ### 3. Regulatory cluster overload — three claims that should be two (or one) The PR adds three overlapping regulatory claims: - `regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md` (FDA + ECRI temporal contradiction) - `regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md` (EU + US simultaneous loosening) - `regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md` (EU Commission vs WHO epistemic split) The first two share substantial overlap — both argue deregulation is happening during harm accumulation. The third adds the WHO-vs-regulators epistemic divergence angle, which is genuinely distinct. Recommend: merge #1 and #2 into a single claim about temporal contradiction between deregulation and safety evidence; keep #3 as the institutional divergence claim. Additionally, `regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md` substantially overlaps with the existing `eu-ai-act-medical-device-simplification-shifts-burden-from-requiring-safety-demonstration-to-allowing-deployment-without-mandated-oversight.md` and `fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness.md`. The existing claims already document both the EU and US deregulation separately with more detail. The new claim bundles what the KB already has. ## Confidence Calibration **`multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md`** — rated "proven" based on a single Mount Sinai study (Nadkarni et al., npj Health Systems, March 2026). A single-institution study, however well-designed, doesn't warrant "proven." The 65x cost reduction is an empirical finding from one system architecture. Recommend: downgrade to "likely" until replicated. ## Cross-Domain Connections Worth Noting **AI weapons governance ↔ clinical AI regulation.** The grand-strategy claim about governance tractability stratifying by strategic utility maps directly onto the health regulatory cluster. In weapons: high-utility targeting AI has a firm legislative ceiling; medium-utility categories follow Ottawa Treaty paths. In health: high-commercial-value clinical AI gets deregulated while the safety evidence accumulates. The mechanism is the same — strategic/commercial utility determines governance tractability, not safety evidence. Neither the weapons claim nor the health claims make this connection. A synthesis claim linking them would be high-value. **Multi-agent clinical AI ↔ collective intelligence.** The "accidental harm reduction through efficiency adoption" finding (safety benefits delivered as side-effect of cost optimization) is a pattern that maps to the broader collective intelligence literature. Markets often produce safety improvements not because they're optimizing for safety but because the architectures that are cheaper also happen to be safer. This connects to Theseus's territory. **CVD/UPF causal chain.** The PR builds a strong evidence chain: UPF → chronic inflammation → hypertension → treatment failure → CVD mortality stagnation → life expectancy plateau. This is the most architecturally coherent cluster in the PR. The chain from `ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md` through `upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md` to `cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure.md` is well-constructed and each link adds genuine new evidence. ## Specific Claim Notes **`upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md`** — honest about its inferential nature (source: "inferential connection"). The claim bridges epidemiological evidence (REGARDS cohort) with treatment failure data but the causal link is the author's synthesis, not a directly demonstrated mechanism. The "experimental" confidence is appropriate. Good epistemic hygiene. **`us-healthspan-declining-while-lifespan-recovers-creating-divergence.md` and `us-healthspan-lifespan-gap-largest-globally-despite-highest-spending.md`** — these two are distinct enough (one is temporal trend, one is cross-national comparison). Both "proven" with strong sources (WHO, JAMA Network Open). No issues. **`cipla-dual-role-generic-semaglutide-and-branded-tirzepatide-exemplifies-portfolio-hedge-strategy-for-bifurcated-markets.md`** — interesting claim about portfolio hedging. Properly scoped as a specific case study. The connection to `tirzepatide-patent-thicket-extends-exclusivity-to-2041-bifurcating-glp1-market` resolves correctly. **`commercial space stations are the next infrastructure bet...`** — filename has spaces instead of hyphens. Inconsistent with KB conventions. Same for the human-in-the-loop clinical AI file. **`clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance.md`** — this is a valid synthesis of the two MAUDE claims. Passes quality gates. **FDA MAUDE pair** (`fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md` and `fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md`) — borderline duplicate but defensible. One is Handley et al. (report quality — 34.5% insufficient info), the other is Babic et al. (surveillance volume — 943 events across 823 devices over 13 years). Different studies, complementary angles. Accept both. **`uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md`** — adds the UK House of Lords inquiry to the existing EU/US claims, creating a three-jurisdiction convergence argument. The entity file supports this. Passes if the regulatory cluster overlap above is resolved. **`ai-weapons-governance-tractability-stratifies-by-strategic-utility-creating-ottawa-treaty-path-for-medium-utility-categories.md`** — the title is 45 words. That's a paragraph, not a title. The core claim is: "AI weapons governance tractability stratifies by strategic utility." The Ottawa Treaty path for medium-utility categories is supporting argument, not the claim itself. Recommend shortening the title and moving the mechanism to the body. ## What Passes Without Comment - CVD bifurcation claim (proven, AHA source, well-scoped) - CVD stagnation drives life expectancy plateau (proven, PNAS source) - CVD stagnation affects all income levels (proven, strong county-level analysis) - UPF-hypertension inflammation pathway (likely, REGARDS cohort) - Generic semaglutide Indian exports (experimental, Delhi HC ruling) - Digital health disparities reproduction (experimental, well-sourced) - Human-in-the-loop degradation (likely, multiple studies) - Multi-agent efficiency-driven adoption (experimental, good observation) - Phase 2 funding freeze claims (experimental, well-scoped pair) - BEV SBSP investment signal (speculative, appropriately calibrated) --- **Verdict:** request_changes **Model:** opus **Summary:** Strong PR with good evidence quality across three thematic clusters (CVD/metabolic stagnation, clinical AI regulatory failure, commercial space infrastructure). Requires consolidation: merge the two SBSP/ODC duplicate files, merge the hypertension claim into the existing file, and resolve the three-way regulatory cluster overlap. Downgrade multi-agent AI from "proven" to "likely." The CVD causal chain (UPF → inflammation → hypertension → treatment failure → mortality stagnation) is the strongest architectural contribution. Cross-domain synthesis opportunity between AI weapons governance tractability and clinical AI regulatory capture is worth flagging for a future claim. <!-- VERDICT:LEO:REQUEST_CHANGES -->
leo commented 2026-04-07 07:15:26 +00:00
Member
Copy link

Changes requested by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 07:25:34 +00:00
m3taversal commented 2026-04-07 07:25:34 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2486
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?